Impact Factor
3.48
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.51
334 total citations
h5-index
24
h5 depth signal
Cited share
83.3%
85 of 102
Total citations
334
Citation footprint
Metric signal
3.60
External metric anchor
Self-citation
0.6%
2 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
138
United Kingdom
74
Italy
69
Australia
26
Canada
22
Citing Fields of Research
Diabetes
180
Endocrinology & Metabolism
176
Nutrition & Dietetics
63
Human Reproduction
38
Endocrine Therapy
35
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,274
Articles tracked across the journal lifetime
Indexed publication set
102
85 cited publications
Last 12 months
44
4.0 publications/month
Open access share
27.3%
12 OA publications in the last year
Leading citing country
United States
138 citing publications
Leading citing field
Diabetes
180 citing publications
Latest tracked publication
11 August 2026
10 recent records available
Coverage & Indexing History
v13n1, 2018-
v13n1, 2018-
Research Focus & Classification
Indexed Subjects
Diabetes
Endocrinology & Metabolism
Broad Categories
Endocrinology
Metabolism
Diabetes
Endocrinology & Metabolism
Nutrition & Dietetics
Human Reproduction
Gut-Brain Axis Disorders
MeSH Descriptors
Endocrine System Diseases
Metabolic Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/17446651.2026.2716201
Open DOI
Opioid-induced adrenal insufficiency: diagnosis and management
02
DOI 10.1080/17446651.2026.2714265
Open DOI
Targeting kidney disease in type 1 diabetes: progress and promise
1. Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by (near-)complete loss of insulin-producing pancreatic β-cells, resulting in lifelong dependence on exogenous insulin. Globa...
03
DOI 10.1080/17446651.2026.2714267
Open DOI
Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues
1. On 14 March 2024 and 15 August 2025, the US Food and Drug Administration (FDA) granted conditional approval of two drugs, resmetirom and semaglutide respectively, for the treatment of metabolic ...
04
DOI 10.1080/17446651.2026.2713482
Open DOI
Crinecerfont: emerging role in the management of congenital adrenal hyperplasia
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare genetic endocrine disorder characterized by impaired cortisol synthesis, excessive adrenal androgen production, and elevated adrenocorticotropic hormone (ACT...
05
DOI 10.1080/17446651.2026.2707565
Open DOI
Improving outcomes through early diagnosis and care in diabetes during pregnancy: are we doing enough?
06
DOI 10.1080/17446651.2026.2707297
Open DOI
Do women with young-onset type 2 diabetes have a higher risk for adverse pregnancy outcomes?
1. Young-onset type 2 diabetes mellitus (YOT2D) is generally defined as a diagnosis of type 2 diabetes (T2D) at under 40 years of age (albeit earlier age cutoffs of 30 and 35 years have been used i...
07
DOI 10.1080/17446651.2026.2698115
Open DOI
Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25-30% of the global population, with the Middle East and North Africa (MENA) region showing some of the highest prevalence rates, reaching up to 40%. MAFLD is a common...
08
DOI 10.1080/17446651.2026.2686629
Open DOI
The relationship between iron deficiency and thyroid function: findings from a population-based study in Jordan
This study aimed to examine the association between iron deficiency (ID) and thyroid dysfunction among Jordanian adults. A cross-sectional analysis was conducted using data from 3,605 participants in a 2017 nationwide survey covering all...
09
DOI 10.1080/17446651.2026.2679517
Open DOI
Beyond normalization: rethinking optimal prolactin levels in prolactinoma management
Prolactinoma, the most common functioning pituitary tumor, poses ongoing challenges due to variable clinical presentation, treatment resistance, and high recurrence rates. While normalization of prolactin (PRL) is a primary therapeutic g...
10
DOI 10.1080/17446651.2026.2676876
Open DOI
Surgical considerations for adult Graves’ disease: a narrative review of indications, perioperative challenges and postoperative outcomes
1. Graves’ disease (GD) is a systemic autoimmune disorder representing the most frequent cause of hyperthyroidism in iodine-replete areas (1). Autoantibodies binding to and unrelentlessly stimulati...
Bibliographical & Catalog Notes
Title from cover.
Latest issue consulted: Vol. 1, no. 4 (July 2006).
Also issued online.